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The immunomodulatory actions of parasitic helminth excretory-secretory (ES) products 
that serendipitously protect against development of chronic inflammatory disorders are 
well established: however, knowledge of the interaction between ES products and the 
host musculoskeletal system in such diseases is limited. In this study, we have focused 
on ES-62, a glycoprotein secreted by the rodent filarial nematode Acanthocheilonema 
viteae that is immunomodulatory by virtue of covalently attached phosphorylcholine (PC) 
moieties, and also two synthetic drug-like PC-based small molecule analogues (SMAs) 
that mimic ES-62’s immunomodulatory activity. We have previously shown that each of 
these molecules prevents development of pathology in collagen-induced arthritis (CIA), 
a model of the musculoskeletal disease rheumatoid arthritis (RA) and reflecting this, we 
now report that ES-62 and its SMAs, modify bone remodeling by altering bone marrow 
progenitors and thus impacting on osteoclastogenesis. Consistent with this, we find 
that these molecules inhibit functional osteoclast differentiation in vitro. Furthermore, this 
appears to be achieved by induction of anti-oxidant response gene expression, thereby 
resulting in reduction of the reactive oxygen species production that is necessary for the 
increased osteoclastogenesis witnessed in musculoskeletal diseases like RA.
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inTrODUcTiOn
The musculoskeletal disease rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory 
condition that results in the debilitating loss of articular bone in affected joints (1). Inflammation in 
such joints is orchestrated by the hyper-proliferative responses of synovial fibroblasts and infiltration 
of activated leukocytes, resulting in bone erosion that can be present prior to manifestation of clinical 
disease (2). Cells associated with bone remodeling such as osteoclasts (OCs), and also immune 
system cells including T and B lymphocytes, rely on cytokines like Receptor Activator of NF-κB 
Ligand (RANKL), osteoprotegerin (OPG), and pro-inflammatory mediators to control cell matu-
ration and pathogenic responses. These events occur in the lymph node and bone marrow (BM) and 
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additionally drive OC differentiation at bone-remodeling sites in 
arthritic joints (3). Thus, in patients with RA, synovial fibroblasts 
and T cells produce increased levels of RANKL and interleukin 
(IL)-17 compared to healthy controls, leading to the dysregulated 
differentiation of OCs at the articular surface, and consequently 
resulting in erosion and deformation of bone (4, 5).
This aberrant osteoclastogenesis contrasts with the tightly 
regulated interactions between OCs and their bone-forming part-
ners, osteoblasts (OBs), that continuously act to maintain homeo-
static renewal of bone (6). In this case, OCs differentiate from 
OC precursors (OCPs) in the monocyte lineage and are recruited 
to the bone, where OBs produce macrophage-colony stimulating 
factor (M-CSF) and RANKL to stimulate terminal OC differen-
tiation (3). The interaction between RANKL and its receptor 
RANK activates the transcription factor NFATc1 which controls 
the production of DC-STAMP and cathepsin K that are essential 
for the fusion and function of mature bone-eroding cells (7–10). 
In addition, the process of osteoclastogenesis is reliant on the 
production of reactive oxygen species (ROS) as both M-CSF and 
RANKL signaling induce ROS to enhance OC differentiation and 
moreover, treatment with N-acetyl-l-cysteine (NAC), a scavenger 
of ROS, inhibits the differentiation of OCs preventing RANKL-
induced ROS (11, 12). Importantly, scavenging ROS with the aid 
of NAC in synovial fibroblasts isolated from RA patients results 
in their decreased RANKL production and inhibited Th17 diffe-
rentiation (13).
Although the immunomodulatory properties of parasitic hel-
minths and their excretory–secretory (ES) products in modulating 
inflammatory diseases including RA are well documented, the 
effects of the helminths or their ES products on bone during such 
conditions remains poorly studied. Among the most widely cha-
racterized helminth ES products is the phosphorylcholine (PC)-
containing glycoprotein ES-62, produced by Acanthocheilonema 
viteae (14, 15). It is well-established that ES-62, via its PC moieties, 
prevents the development and progression of arthritic disease, 
with histopathological analysis demonstrating that it not only 
suppresses inflammatory cell infiltration of the joints, but also 
reduces cartilage and bone damage, in the murine model of RA, 
collagen-induced arthritis (CIA) (14, 16, 17). Specifically, ES-62 
promotes IL-22-mediated tissue repair responses in the joint, 
while disrupting Th17 and IL-17-producing γδ T  cell inflam-
matory networks to facilitate the resolution of disease (16, 17). 
Likewise, drug-like small molecule analogues (SMAs) based on 
the active PC moiety of ES-62 mimic both the anti-inflammatory 
and bone protective effects of ES-62 and thereby prevent the 
devel opment and progression of joint damage associated with 
arthritis in CIA (18–20).
We, therefore, aimed to investigate whether these helminth-
derived agents could also impact on pathogenic osteoclastogen-
esis to resolve inflammation and joint damage in the CIA model. 
In doing so, we have established that treatment with ES-62 can 
alter BM monocyte populations in vivo and reduce functional OC 
differentiation in  vitro. We also demonstrate that the drug-like 
SMAs based on this helminth product, mimic ES-62’s ability to 
modulate OC differentiation in  vitro by orchestrating an anti-
oxidant response that suppresses ROS production.
MaTerials anD MeThODs
animals
Male 6- to 8-week-old C57BL/6 mice were bred and maintained 
under specified pathogen-free and standard ad  libitum condi-
tions at the University of Strathclyde’s Biological Procedures 
Unit. Male 6- to 8-week-old DBA/1 mice (Envigo; Bicester, UK) 
were housed and maintained in the Central Research Facility of 
the University of Glasgow. All experiments were approved by, and 
conducted in accordance with, the Animal Welfare and Ethical 
Review Boards of the Universities of Strathclyde and Glasgow and 
UK Home Office Regulations and Licenses PIL I518666F7, PPL 
60/4314, PPL P8C60C865, PIL 1675F0C46, and PIL ICEBDB864.
collagen-induced arthritis
Collagen-induced arthritis (CIA) was induced in male DBA/1 
mice (8- to 10-week-old; ~ 20 g) following intradermal immuni-
zation with 100 µg of bovine collagen type II (CII) emulsified with 
complete Freud’s adjuvant (MD Biosciences) on day 0 with a fur-
ther injection of 200 µg CII in PBS given intraperitoneally on day 21 
as described previously (14). Animals were treated via the subcutane-
ous route with either PBS or 2 μg/injection of ES-62 (~ 0.1 mg/kg) 
on days −2, 0, and 21 and joint inflammation was scored as previ-
ously described (14). Disease articular scores were assessed daily as 
0 (normal), 1 (erythema), 2 (erythema plus swelling), 3 (extension 
of swelling), or 4 (loss of function), with the overall score being 
the sum of those from all four limbs: animals were culled when 
indicated or at least one of the PBS control group had reached a 
score of 10 or clinical symptoms developed in all four limbs. Joint 
damage was also routinely assessed by histopathology. Typically, 
disease incidences ≥80%, where incidence is defined as the per-
centage of animals achieving an articular score ≥1, are achieved 
by about day 30, with articular scores generally plateauing around 
this time (14, 16–21). Purified endotoxin-free ES-62 and SMAs 
11a, 12b, and 19o were prepared as previously described (14, 18).
histology
Paws from CIA mice were fixed in 4% paraformaldehyde prior 
to decalcification and paraffin wax embedding for H&E staining 
(7  µm sections) following a standard protocol. For cathepsin 
K detection by immunofluorescence, sections were cleared in 
histoclear and rehydrated before antigen retrieval in citrate 
buffer for 20 min at 95°C. Sections were blocked in 10% FBS in 
PBS for 30 min at room temperature (RT), endogenous avidin/
biotin was quenched (Vector Laboratories, UK), and sections 
incubated overnight at 4°C with rabbit anti-mouse cathepsin 
K (Abcam, UK). Sections were then incubated for 60  min at 
RT with biotinylated goat anti-rabbit IgG (Vector Laboratories, 
UK) and followed with streptavidin-conjugated Alexa Fluor 647 
(Vector Laboratories, UK) for 30  min at RT. DAPI (1  µg/ml) 
was used as a nuclear stain (Sigma-Aldrich, UK). Sections were 
washed in PBS with 0.05% (v/v) Tween-20 between each incu-
bation. Following staining, sections were dehydrated through 
ethanol, mounted, and cathepsin K+ multinucleated cells on 
the bone surface were enumerated using an EVOS FL Auto Cell 
Imaging System.
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Flow cytometry
BM cells were suspended in FACS buffer (2.5% BSA; 0.5  mM 
EDTA, in PBS) following red cell-lysis with 0.8% NH4Cl 
buffer. Phenotypic surface markers were labeled using 
PE-conjugated anti-CD3/B220/Ter119, FITC anti-CD11b, PerCP- 
Cy5.5 anti-Ly6C, APC anti-Ly6G or CD11b, and Biotin anti-CD115 
antibodies and APC Cy7 conjugated streptavidin (Biolegend). Cells 
were stained with 7AAD (BD Bioscience, UK) to assess cell death. 
For hematopoietic stem cell (HSC) analysis, PE-conjugated lin-
eage cocktail and PE-conjugated isotype antibodies were used 
alongside FITC anti-Sca-1 and APC anti-CD117 antibodies. Data 
were acquired using a FACS Canto flow cytometer and analyzed 
using FlowJo Software (Tree Star Inc, OR, USA, version 8.8.7) 
and populations were gated using isotype and fluorescence minus 
one controls.
In Vitro Oc Differentiation
Osteoclasts (OCs) were differentiated from naïve C57BL/6 or 
DBA/1 mice that were either naïve control animals or DBA/1 
mice that had undergone CIA and received either PBS or ES-62 
treatments, in vivo. BM was flushed from the tibias and femurs 
of these mice using a sterile 23G needle and syringe in PBS 
and aspirated to create a single cell suspension. This single cell 
suspension was then passed through a 20 µm cell strainer prior 
to centrifugation at 400 × g and re-suspension in PBS. Following 
cell counting, single cells were washed and re-suspended at 
1 × 106/ml in “complete” αMEM medium (containing 50 U/ml 
penicillin, 50  µg/ml streptomycin, and 10% FCS) and 9  ml of 
cell suspension were incubated overnight with 30 ng/ml M-CSF 
(Peprotech, London, UK). Following overnight incubation at 
37°C in 5% CO2, non-adherent BM cells were removed, counted, 
and re-suspended in fresh complete αMEM medium supple-
mented with 30 ng/ml M-CSF and 50 ng/ml RANKL at 0.5 × 106 
cells/ml. These non-adherent BM cells (200 µl) were then seeded 
in 96-well tissue-culture plates to initiate OC differentiation. 
Preliminary experiments established that while treatment of cells 
with phosphorylcholine conjugated to bovine serum albumin 
(PC-BSA) from day 1–4 did not inhibit the numbers of OCs 
generated, exposure to PC-BSA at day 4 resulted in inhibition of 
the OC fusion underpinning generation of large multinucleated 
OCs (data not shown). Thus medium was refreshed on day 4 and 
treated with vehicle, ES-62, bovine serum albumin (BSA—Sigma-
Aldrich, UK), phosphorylcholine conjugated to BSA (PC-BSA) 
(22), phosphorylcholine chloride (PC—Sigma, UK), or SMAs 
11a, 12b, or 19o, at the indicated concentrations, for 24 h prior to 
assessment of functional maturation. Cells were assessed for OC 
differentiation by TRAP staining (Leukocyte Acid Phosphatase 
Kit, Sigma, UK) on days 4, 5, and 6 as indicated and cells that 
stained positive for TRAP with ≥3 nuclei were counted as OCs. 
The average size of individual OCs per field of view (FOV) was 
calculated using Image J software. Images were obtained on an 
EVOS FL Auto Cell Imaging System or a Leica DM IL LED at 4× 
magnification with scale bars set at 1,000 µm.
In Vitro Bone resorption assay
Dentine Discs (Immunodiagnostics Systems Ltd., UK) were used 
to measure the functional capacity of differentiated OCs. Briefly, 
non-adherent BM was cultured on dentine discs for 14 days with 
medium refreshed every fourth day. Vehicle controls and treat-
ments were commenced on day 4 and added with every medium 
replacement. OCs were lysed on dentine discs by incubation with 
distilled H2O prior to visualization of resorption pits using black 
ink. The area of resorption was measured as a percentage of the 
total area using ImageJ software. Images were obtained on an 
EVOS FL Auto Cell Imaging System or a Leica DM IL LED at 
10× magnification with scale bars set at 400 µm.
qrT-Pcr
BM cells (106), or OCs that were pre-treated with SMAs (5  µg/
ml) for 24 h, were lysed in RNeasy lysis buffer prior to mRNA 
extraction using an RNeasy Plus Mini kit (Qiagen, Germany) 
according to manufacturer’s instructions. Additionally, cleaned and 
flushed femurs and tibias were then flushed with QIAzol to obtain 
RNA from bone-lining cells as previously described (23). cDNA 
was generated using a high capacity cDNA Reverse Transcriptase kit 
(Applied Biosystems, Life Technology) before use in PCR ampli-
fications using the StepOne Plus™ real-time PCR system (Applied 
Biosystems). KiCqStart® qPCR Ready Mix (Sigma-Aldrich) was 
used in conjunction with the following primer pairs: osteopontin 
(OPN) (spp1; forward—GGATGAATCTGACGAATCTC, reverse— 
GCATCAGGATACTGTTCATC), RANK (tnfrsf11a; Forward— 
GAAATAAGGAGTCCTCAGGG, reverse—TAGAATCTCTGA 
CTTCTGCC), RANKL (tnfsf11; forward—TCTGTTCCTGTACTT 
TCGAG, reverse—TTCATGGAGTCTCAGGATTC), OPG (tnfrsf11b; 
forward—GAAGATCATCCAAGACATTGAC, reverse—TCCT 
CCATAAACTGAGTAGC), DC-STAMP (dcstamp; forward—TC 
TGCTGTATCGGCTCATCTC, reverse—ACTCCTTGGGTTCC 
TTGCTT), Cathepsin K (ctsk; forward—CAGAGGGTACAGAG 
AGATTC, reverse—TCATCATAGTACACACCTCTG), MMP9 
(mmp9; forward—CTTCCAGTACCAAGACAAAG, reverse— 
ACCTTGTTCACCTCATTTTG), NFATc1 (nfatc1; forward—CC 
AAGTCAGTTTCTATGTCTG, reverse—ATAATTGGAACATT 
GGCAGG), β3 (itgb3; forward—TATAGTGAGCTCATTCCTGG, 
reverse—ATTTTCCCGTAAGCATCAAC), and β-actin (actb; 
forward—GATGTATGAAGGCTTTGGTC, reverse—TGTGCA 
CTTTTATTGGTCTC). TaqMan™ master mix (Applied Bio-
systems) was used to analyze the following set of genes; heme 
oxygenase-1 (HMOX1) (Hmox1—Mm00516005_m1), GCLM (gclm—
Mm00514994_m1), GCLC (gclc—Mm00802655_m1), and 
GAPDH (gapdh—Mm99999915_g1). Data were normalized to 
the reference genes GAPDH or β-actin to obtain the ΔCT values 
that were used to calculate the fold-change from the ΔΔCT fol-
lowing normalization to the biological control group.
rOs assay
The presence of ROS was measured on day 5 of the OC differ-
entiation assay, following 24 h pre-treatment with SMAs, using 
2′,7′-dichlorofluorescein diacetate (DCF-DA, Sigma, UK). Briefly, 
to measure ROS, cells were washed in pre-warmed PBS twice 
prior to incubation with 100 µl of 50 µM DCF-DA for 30 min 
at 37°C. Following washing in PBS, fluorescence was detected at 
492 nm excitation and 529 nm emission wavelengths. Unstained 
cells were used to control for background fluorescence and bio-
logical replicates were normalized to controls.
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statistics
All data were analyzed using GraphPad Prism 6 software. For para-
metric data, Student’s t-test or one-way ANOVA with Bonferroni’s 
or Fishers LSD post-tests were employed. Non-parametric data 
were analyzed using Kruskal–Wallis test and Dunn’s post-test or 
Mann–Whitney U test. Indicators of significance include *p < 0.05, 
**p < 0.01, and ***p < 0.001.
resUlTs
es-62 normalizes the BM Oc Progenitor 
Populations in arthritic animals
In line with our previously published observations (14), DBA/1 
mice treated with ES-62 were protected from developing arthritis 
in the CIA model both in terms of articular score (Figures 1A,B) 
and disease incidence (Figure 1A: PBS, 87.5%; ES-62, 0%, at cull). 
This impact of ES-62 on disease pathology was confirmed by H&E 
staining of joint sections (Figure 1C), which showed that expo-
sure to the parasite product reduced inflammatory cell infiltration 
and cartilage and bone destruction. Additionally, upon analysis 
of representative animals from each group, the levels of cathepsin 
K+ OCs found in such sections were decreased in the paws of ES- 
62-treated animals compared to those of PBS-treated CIA animals, 
returning to the levels found in joints from naïve healthy DBA/1 
mice (Figures 1D,E). To understand the effect of inflammatory 
arthritis on BM progenitors we identified hematopoietic stem 
cells (HSCs) within the BM of animals undergoing CIA. Analysis 
of Sca-1+CD117+ cells within the Lineageneg population showed 
that PBS-treated CIA animals had an increased proportion of 
HSCs in the BM compared to both naïve and ES-62-treated CIA 
animals (Figure 1F). The BM HSC population is supported and 
maintained by stromal and OB production of OPN, but analysis 
of OPN mRNA in the bone-lining cells (23) of the femurs and tibias 
showed that OPN mRNA levels were not significantly different in 
PBS-treated CIA mice relative to naïve and ES-62-treated CIA 
animals (Figure  1G). As ES-62 is able to return HSC levels to 
those found in healthy animals and show evidence of reducing 
cathepsin K+ OC numbers in the joints of arthritic mice, we 
next aimed to determine specifically whether CIA would affect 
defined OC progenitor populations in the BM. Due to their dif-
ferentiation from the myeloid lineage, we focused on phenotypic 
analysis of both monocyte (CD3−B220−Ter119−Ly6G−Ly6Chigh) 
and OCP (CD3−B220−Ter119−Ly6G−Ly6ChighCD11blow) popula-
tions (Figure  1H), as OCPs constitute a small population of 
cells within the umbrella of monocyte heterogeneity, as defined 
by Charles et al. (24). Our analysis showed that treatment with 
ES-62 reduced the absolute percentage (%) of monocytes within 
the BM of mice undergoing CIA (Figure  1I). Moreover, CIA 
(PBS) increased the % of OCPs in the BM compared to naïve 
animals (Figure 1J): although treatment with ES-62 was unable 
to significantly alter the level of BM OCP populations observed 
from that in PBS-treated CIA animals, the % of OCPs present in 
ES-62-treated CIA animals was not significantly different from 
that of naïve animals, suggesting that ES-62 was having some 
effect in reducing the % of these progenitor cells in BM of CIA 
animals. In addition, ES-62 treatment was able to decrease the 
expression of CD115 (the M-CSF receptor) on the surface of both 
monocytes (Figure 1K) and OCPs (Figure 1L) compared to PBS-
treated CIA animals, an effect that would decrease their ability to 
differentiate into OCs during inflammation.
es-62 alters the Functional Differentiation 
of Ocs and the Bone-remodeling axis  
in arthritic animals
Previously, exposure to ES-62 was found to alter differentiation 
of macrophages from BM progenitors (25) and, therefore, given 
its effects on OCPs, we next aimed to investigate whether OC 
differentiation from ES-62-treated CIA-mouse BM was altered 
compared to that from PBS-treated CIA animals. OCs are short- 
lived cells with their apoptosis playing roles in regulating oste-
oclastogenesis (26, 27): thus, due to the dynamic nature of their 
differentiation and cell death (26), a time course of OC diffe-
rentiation was performed to observe the effects of in  vivo 
exposure to ES-62 on the kinetics and extent of differentiation 
of OCs derived from BM of mice undergoing CIA. As shown in 
Figures 2A,B, by day 4 comparable levels of osteoclastogenesis 
in terms of OC number and size were observed among treatment 
groups: however, by day 5, there was a significant increase in cell 
fusion associated with CIA resulting in a decrease in cell num-
ber, but an increase in cell size in the PBS-treated CIA animals 
compared to naïve and ES-62 treated animals. By the sixth day of 
culture the majority of large multinucleated cells have begun to 
apoptose (Figure 2C) with similar levels of live cells remaining 
in the PBS- and ES-62-treated groups. Representative images of 
OC differentiation are provided with cell death indicated by red 
arrows (Figure 2C). To assess the functional capacity of the BM 
progenitors from naïve and PBS- and ES-62-treated CIA animals, 
the BM was cultured for 14 days on dentine slices, revealing that 
ES-62-CIA BM had a reduced ability to resorb bone compared to 
PBS-CIA BM (Figures 2D,E).
In order to further understand how the inflammatory milieu 
in arthritic animals influences the OC progenitor populations 
and the differentiation potential of OCs, the RANK/OPG/
RANKL bone-remodeling axis was analyzed. Whole BM lysates, 
collected at cull, were used to analyze the mRNA transcripts of 
RANK (tnfrsf11a), OPG (tnfrsf11b), and RANKL (tnfsf11) to 
identify potential changes that occur during disease and that may 
be (differentially) modified following treatment with ES-62. As 
shown in Figure 2F, the mRNA level for RANK was not signifi-
cantly changed in PBS-treated CIA animals compared to naïve 
controls. However, treatment with ES-62 resulted in a decrease in 
RANK transcript. Similarly, OPG mRNA levels were unchanged 
in PBS-treated animals compared to naïve animals, however, 
ES-62 treatment increased OPG mRNA in the BM of animals, 
although this did not reach statistical significance (Figure 2G). 
No changes were observed in RANKL mRNA levels between 
naïve and PBS-treated animals, while ES-62 treatment strikingly 
decreased RANKL mRNA compared to PBS-treated CIA animals 
(Figure 2H).
Overall, the data in Figures  1 and 2 indicate that arthritic 
disease in DBA/1 animals undergoing CIA alters both the levels 
of OC progenitor populations and their potential to form large 
FigUre 1 | Continued
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FigUre 1 | ES-62 alters the progenitor populations in the BM of arthritic animals. Arthritic scores of DBA/1 mice undergoing CIA from challenge until cull at day 29 
(PBS-treated CIA animals, n = 8; ES-62-treated CIA animals, n = 6) (a) and the scores of all animals used in the study obtained from four independent CIA models at 
cull [PBS-treated (n = 30) and ES-62-treated (n = 20) CIA animals] (B). Joint sections of representative animals (PBS-CIA, score 7 and ES-62-CIA, score 0) in each 
treatment group were subjected to histological analysis employing H&E staining [(c) scale bar = 400 µm] and analysis of expression of cathepsin K by 
immunofluorescence [(D) DAPI, blue; cathepsin K, red; scale bar = 500 µm]. The number of cathepsin K+ multinucleated cells within the joints of animals [naïve 
(n = 4), PBS (n = 3), and ES-62 (n = 4); three field of view (FOV) per sample] were enumerated (e). BM was taken from naïve (n = 8), PBS (n = 12), and ES-62 (n = 7) 
treated CIA animals to analyze the frequency of hematopoietic stem cells (HSCs—LineagenegSca-1+CD117+) (F). QIAzol lysates of bone-lining cells from the femur and 
tibia of animals were analyzed for osteopontin (OPN) mRNA (naïve, n = 4; PBS, n = 8; ES-62, n = 7) (g). BM from CIA animals was analyzed by flow cytometry for the 
phenotypic markers of monocytes and OC precursors (OCPs) following gating of single CD3−B220−Ter119− cells. The gating strategy for distinguishing monocytes 
from neutrophils is demonstrated (Ly6ChighLy6G− population) and this is subsequently used to identify the OCPs (CD11blowLy6ChighLy6G− population) that reside within 
the global monocyte population (h). The percentage of monocytes and OC precursors (i,J) from naïve (n = 24), PBS-treated [n = 26 for (i) and 30 for (J)], and 
ES-62-treated (n = 19) CIA animals as well as the expression of CD115 on the surface of monocytes and OC precursors [(K,l); naïve, n = 4; PBS, n = 8; ES-62, 
n = 7] was examined. Data are pooled from four independent experiments and are presented as mean values of individual mice ± SEM. Two-tailed Mann–Whitney 
t-test or Kruskal–Wallis with Dunn’s multiple comparisons was used for non-parametric data and one-way ANOVA with Fishers LSD was used to analyze parametric 
data where *p < 0.05, **p < 0.01, and ***p < 0.001.
FigUre 2 | Continued
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FigUre 2 | Exposure to ES-62 in vivo alters the ex vivo responses of OC progenitors and decreases RANKL mRNA in the bone marrow (BM) of arthritic animals. 
Non-adherent BM, naïve (n = 3), PBS-treated CIA (n = 3), and ES-62-treated CIA (n = 3) from DBA/1 mice, was harvested at cull and cultured for 4–6 days with 
30 ng/ml M-CSF and 50 ng/ml RANKL. Medium was refreshed on day 4 and OC differentiation was assessed by TRAP staining. The number (a) and size (B) of live 
TRAP+ multinucleated OCs with >3 nuclei were calculated using ImageJ analysis software. Representative images of OCs (PBS-CIA, score 10 and ES-62-CIA, 
score 0) at each time point are provided with red arrows indicating dead OCs [(c) scale bar = 1,000 µm]. Data are from one experiment performed in triplicate 
presented as mean ± SD and are representative of two experiments, although the kinetic profile of OC differentiation was observed with BM from three mouse 
models comparing naive and PBS-CIA mice. Representative images of dentine slices following 14-day culture with OCs from naïve (n = 3), PBS (mean score 6; 
n = 4), or ES-62 (mean score 3; n = 4)-treated CIA-animal BM [(D) scale bar = 400 µm]. ImageJ software was used to calculate the % of resorption and data are 
presented as mean ± SEM of individual mice performed in triplicate (e). mRNA transcripts from naïve (n = 4), PBS-treated CIA (n = 8), and ES-62-treated CIA 
(n = 7) animals, collected at cull, were analyzed for (F) RANK (tnfrsf11a), (g) OPG (tnfrsf11b), and (h) RANKL (tnfsf11). Data from a single experiment are shown as 
mean values (of triplicate analyses) ± SEM of individual mice and are representative of four experiments. Two-way ANOVA with Fisher’s LSD post-test was used to 
analyze experimental conditions comparing PBS-treated CIA with naïve and ES-62-treated CIA animals, where ***p < 0.001. Kruskal–Wallis with Dunn’s post-test 
was used to analyze non-parametric data, where *p < 0.05 and **p < 0.01.
7
Doonan et al. ES-62 Inhibits Osteoclastogenesis
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1016
multinucleated OCs, while the helminth product ES-62 acts to 
restore the level of OCPs to that resembling BM OCPs from naïve 
DBA/1 animals and inhibit their functional maturation. While 
the RANK/RANKL/OPG bone-remodeling axis is not substan-
tially altered during CIA, the changes in RANK/RANKL/OPG 
mRNA induced by ES-62 treatment may account for the modu-
lation of progenitor populations and their subsequent capacity 
to undergo osteoclastogenesis and indicate that ES-62 does not 
simply prevent the rewiring of progenitors occurring in the naïve 
to CIA transition.
es-62 Modulates Differentiation of 
Osteoclast Functional responses In Vitro
To directly address the mechanisms involved in ES-62-mediated 
modulation of OC responses, BM was cultured with M-CSF and 
RANKL for 5 days and naïve BM from both DBA/1 and C57BL/6 
mouse strains was employed, the latter to allow us to examine 
the potential for differences in OC differentiation and functional 
maturation between arthritis-prone and more resistant strains, 
respectively (28). Addition of ES-62 at day 4 did not inhibit OC 
differentiation in C57BL/6 animals, but significantly inhibited 
OC fusion that generates large, multinucleated cells in a dose-
dependent manner, with maximum inhibition at the highest con-
centration tested, 50 µg/ml (data not shown and Figures 3A,B,E). 
While addition of ES-62 to DBA/1 cultures likewise significantly 
dec reased the size of the resulting TRAP+ OCs, it also reduced 
the numbers of OCs differentiated from the BM of naive DBA/1 
mice (Figures 3C–E).
PC (PC chloride) and PC conjugated to BSA (PC-BSA) were 
also tested in OC differentiation assays to determine whether the 
immunomodulatory PC-component of ES-62 was responsible for 
this novel effect on OCs. In the arthritis-resistant C57BL/6 ani-
mals, PC-BSA, but not PC, significantly increased the number of 
OCs in culture, yet PC-BSA and PC treatment both generated OCs 
that were smaller in size than those in the M-CSF and RANKL 
controls (Figures  3A,B). In DBA/1 animals, neither PC-BSA 
nor PC had an effect on the number of OCs generated but like 
ES-62, both significantly reduced the fusion of OCs resulting in 
smaller TRAP+ OCs (Figures 3C–E). BSA was used as a control 
for PC-BSA treatment and was shown to have no effect on the dif-
ferentiation and functional maturation of OCs in either C57BL/6 
or DBA/1 cultures (Figures 3A–E). Representative images are 
provided to demonstrate the inhibition in OC fusion observed in 
both C57BL/6 and DBA/1 BM cultures (Figure 3E).
The bone resorption assay was then utilized to understand 
how ES-62 and the PC-containing molecules were affecting the 
functional capacity of the OCs undergoing reduced cell fusion 
during in vitro osteoclastogenesis. This showed that ES-62 (albeit 
not significantly relative to the M +  R control) and PC-BSA 
reduced the levels of bone resorption induced compared to those 
in M-CSF plus RANKL controls (±BSA, Figures  3F,G). These 
effects on osteoclastogenesis were not due to reduced cell viability 
as 7AAD staining showed that treatment with ES-62, PC-BSA, 
PC, or BSA all further reduced the very low levels of dead (% of 
7AAD+CD11b+) cells resulting in culture when compared to those 
with M-CSF plus RANKL alone (M + R; Figure 3H). Collectively, 
these data indicate that the immunomodulatory PC component of 
ES-62 is likely to be responsible for its ability to inhibit fusion and 
functional maturation of OCs. Moreover, the data suggest that 
exposure to ES-62/PC in vitro prevents the functional maturation 
of OCs derived from BM OCPs from both healthy C57BL/6 and 
DBA/1 mice, predominantly by recapitulating the reduced OC 
fusion found during ex vivo osteoclastogenesis of BM from CIA 
mice exposed to ES-62 in vivo (Figure 2).
es-62’s sMas 11a and 12b inhibit 
Osteoclast Differentiation and  
Functional Maturation
The PC moiety of ES-62 has been used as the structural start-
ing point to generate a library of drug-like synthetic SMAs that 
mimic the immunomodulatory capabilities of ES-62: two of 
these, SMAs 11a and 12b recapitulate the anti-inflammatory and 
bone protective effects of ES-62 and are successful in preventing 
development and progression of joint damage in CIA (18–20). 
Thus, we investigated the effect of these compounds on in vitro 
OC differentiation, with addition of SMAs 11a or 12b (at 5 µg/ml) 
on day 4. SMA 19o was used as a negative control for SMAs 
11a and 12b, as in previous studies this SMA failed to mimic 
the protective immunomodulatory capabilities of ES-62, either 
in  vivo or in  vitro (18, 29). In C57BL/6 and DBA/1 cultures, 
SMAs 11a and 12b significantly reduced both the number and 
the size of differentiated OCs, compared to M +  R exposure 
alone while, by comparison, SMA 19o exhibited little or no effect 
FigUre 3 | ES-62, and PC inhibit the fusion of OCs in vitro. Non-adherent bone marrow (BM), from healthy naïve C57BL/6 and DBA/1 mice was harvested and 
cultured for 4 days with 30 ng/ml M-CSF and 50 ng/ml RANKL, at which point, medium was removed and cells were incubated in fresh medium or medium 
containing 50 µg/ml of ES-62, PC, PC conjugated to BSA (PC-BSA), or BSA. OC differentiation at day 5 was assessed by TRAP staining and ImageJ was employed 
to measure the number and size of multinucleated OCs with >3 nuclei present (a–D). Representative images of experimental conditions are provided [(e) scale 
bar = 1,000 µm]. To assess the ability of ES-62 to inhibit OC bone resorption, naïve C57BL/6 non-adherent BM was cultured on dentine slices with BSA, ES-62, 
PC-BSA, or PC treatment commencing from day 4 until day 14 when resorption was assessed and representative images are provided [(F,g) scale bar = 400 µm]. 
The effect following 24 h pre-treatment of ES-62, BSA, PC-BSA, or PC on cell viability was assessed using 7AAD+CD11b+ cells by flow cytometry (h). Data are 
pooled from four [(a–D); ES-62 treatment was only performed in two of these experiments]; two [(g): ES-62 treatment reduced the capacity of the cells to resorb 
bone in both experiments but this inhibition was only significant compared to the control cells in one experiment]; or three (h) independent experiments performed in 
triplicate and presented as mean ± SEM. Data were analyzed using one-way ANOVA with Fisher’s LSD post-test to compare experimental conditions to M + R, 
where *p < 0.05, **p < 0.01, and ***p < 0.001.
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FigUre 4 | SMAs of ES-62 inhibit the differentiation and function of OCs. 
Non-adherent bone marrow (BM) from naïve C57BL/6 and DBA/1 mice was 
harvested and cultured for 4 days with 30 ng/ml M-CSF and 50 ng/ml 
RANKL, at which point medium was refreshed and cells were incubated in 
medium or medium containing 5 µg/ml SMA 11a, 12b, or 19o. OC 
differentiation was assessed at day 5 by TRAP staining and Image J was 
employed to measure the number and size of OCs present (a–D). 
Representative images of TRAP-stained SMA-treated OCs are provided [(e) 
scale bar = 1,000 µm]. The functional capacity of SMA-treated C57BL/6 OCs 
was assessed on dentine slices after 14 days, where SMAs were added 
when medium was refreshed from day 4 onward and representative images 
of resorption pits provided [(F,g) scale bar = 400 µm]. OC precursor cell 
death following 24-h treatment with SMAs using 7AAD staining was 
measured (h). Data are from three experiments performed in triplicate and 
presented as mean ± SD. One-way ANOVA with Fisher’s LSD post-test was 
used to analyze experimental conditions compared to M + R, where 
*p < 0.05, **p < 0.01, and ***p < 0.001. In (g), 19o is not significantly 
different to M + R but is significantly different to 11a (p < 0.001) and 12b 
(p < 0.05).
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(Figures 4A–D). Representative images of SMA-treated C57BL/6 
OCs are provided to highlight the reduction in the size of OCs 
compared to those produced following culture with M  +  R 
(Figure 4E). Furthermore, assessment of the ability of the SMAs 
to modulate OC function in the bone resorption assay showed 
that while SMA 19o, if anything, tended to promote bone resorp-
tion, SMA 11a and, to a lesser extent, 12b (albeit only significantly 
with respect to the SMA 19o control) inhibited bone resorption 
(Figures 4F,G).
Due to their therapeutic potential, we wished to ensure that 
the effects of the SMAs did not reflect induction of cell death: 
importantly analysis of cell viability showed that the % of 7AAD+ 
CD11b+ cells in SMA-treated cultures is not increased relative 
to M + R treatment alone (Figure 4H). Therefore, the effects of 
SMAs on OC differentiation and functional maturation are not 
due to cell death, findings consistent not only with our previous 
reports on SMA-treated macrophages (18, 19), but also with the 
effects of ES-62, PC-BSA, and PC observed in Figure 3H.
sMas 11a and 12b alter mrna 
Transcription in Ocs and induce  
an anti-Oxidant response
To identify the mechanisms underlying the observed SMA-
mediated effects, the inhibition of OC differentiation by SMA 
11a or 12b was further explored by examination of expression 
of key regulators of OC differentiation and function on cells that 
had been in culture for 5  days (Figures  5A–E). Interestingly, 
despite inhibiting differentiation and resorption, SMA 11a failed 
to have any effect on mRNA levels of the OC-specific genes 
investigated (Figures  5A–E), suggesting that this SMA utilizes 
another mechanism to inhibit functional differentiation of OCs. 
By contrast, SMA 12b was able to decrease the mRNA levels of 
a number of essential OC genes (Figures 5A–E). For example, the 
master regulator of osteoclastogenesis, NFATc1, was decreased 
following SMA 12b exposure (Figure 5A) and indeed, inhibition 
of this transcription factor by SMA 12b is likely to account for 
its effects on expression of the key markers of OC differentiation, 
MMP9, cathepsin K, DC-STAMP, and ß3 (Figures 5B–E) (10, 30) 
and perhaps explains its dramatic effects on the differentiation 
and fusion of TRAP+ OCs. As expected, SMA 19o generally had 
little or no effect in this analysis.
Previously, SMA 12b was shown to require NRF2 for its inhibi-
tion of pro-inflammatory cytokine release by macrophages (19), 
particularly that of IL-1β which also plays a key role in promoting 
osteoclastogenesis and bone resorption (31). As SMA 12b-mediated 
protection appeared to reflect induction of NRF2-regulated anti-
oxidant genes (19) and NRF2 is a known inhibitor of OC differ-
entiation (32), we next investigated the effect of the SMAs on the 
induction of NRF2 response genes in day 5 OCs. This showed that 
both SMA 11a and 12b, but not 19o, increased mRNA for heme 
oxygenase-1 (HMOX1), GCLC, and GCLM (Figures 5F–H). This 
dramatic increase in anti-oxidant response gene mRNA was mir-
rored by a significant reduction in the level of ROS produced by OCs 
following exposure to SMA 11a or 12b but not 19o (Figure 5I). As 
M-CSF and RANKL, individually and in combination, stimulate a 
ROS response that is required for the differentiation of mature OCs 
FigUre 5 | SMA 12b downregulates OC-specific gene transcription and induces an antioxidant response during OC differentiation in vitro. Non-adherent BM, from 
C57BL/6 mice, was harvested and cultured for 4 days with 30 ng/ml M-CSF and 50 ng/ml RANKL (M + R), at which point medium was refreshed and cells were 
incubated in medium or medium containing 5 µg/ml of SMAs 11a, 12b, or 19o. At day 5 of culture, OCs were lysed, mRNA extracted, and cDNA synthesized. 
Expression of nfatc1 (a), mmp9 (B), ctsk (c), dc-stamp (D), itgb3 (e), hmox-1 (F), gclc (g), and gclm (h) mRNA was determined by qRT-PCR to assess the 
phenotypic profile of OCs. Likewise, on day 5 of culture, following the 24-h treatment with SMAs, OCs (i) were stained using the fluorescent stain DCF-DA to 
measure the presence of reactive oxygen species (ROS). Data are collated from three experiments performed in triplicate, normalized to the M + R control and 
presented as mean ± SD. One-way ANOVA with Dunn’s post-test was used to analyze experimental conditions compared to M + R, where *p < 0.05, **p < 0.01, 
and ***p < 0.001.
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(11, 12), this inverse increase in anti-oxidant response genes and 
decrease in OC ROS production following SMA treatment provides 
a potential mechanism for the ability of both SMA 11a and 12b to 
inhibit OC fusion and function despite the failure of SMA 11a to alter 
the levels of markers associated with driving osteoclastogenesis. The 
combination of decreased ROS and regulators of OC differentiation 
presumably explains the increased efficacy of SMA 12b (relative to 
11a) in suppressing functional maturation of OCs, although 11a was 
more effective at preventing bone resorption.
DiscUssiOn
It has been widely established that helminths are capable of skew-
ing immune responses in order to improve their survival and 
prevent expulsion from the host and that this can impact on other 
infections as well as medical conditions associated with aberrant 
inflammatory responses (33). In the context of their potential 
protection against arthritis, helminths promote a strong Th2 
immune response that is thought to counter the Th1/17 responses 
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that dominate this disease (34). However, previously, our work 
has demonstrated that the helminth product ES-62 disrupts the 
IL-17 network in arthritis models without promoting a Th2 phe-
notype: rather, by resetting homeostatic regulatory mechanisms 
(regulatory B cell and IL-22-dependent synovial fibroblast tissue 
repair responses), ES-62 acts to interfere with a number of the 
key pathological processes required to drive inflammation and 
disease (14, 17, 22, 35). Thus, this single ES product adopts a 
mechanism of action distinct from that commonly observed with 
live helminth infections, but that effectively redirects the immune 
system away from its state of hyper-responsiveness.
Herein, we now show that ES-62 also protects against the 
development of arthritis in the CIA model by modulating the 
progenitor populations that directly impact on bone remodeling 
in arthritic disease. Thus, consistent with its ability to reset 
homeostatic regulation, ES-62 exhibited an ability to return the 
levels of HSC and OC BM progenitors found in arthritic animals 
toward those found in healthy, “Naïve” animals and also to skew 
the RANK/OPG/RANKL axis such that OCPs would be less 
responsive to pathogenic signaling and result in less cathepsin 
K+ OCs differentiating in the inflamed joint. Furthermore, 
in line with the finding that OCPs in the BM are increased in 
the SKG spontaneous model of arthritis (24), we witnessed an 
increase in the monocyte and OCP populations in animals with 
CIA whilst treatment of these animals with ES-62 returned the 
numbers of monocytes, and potentially OCPs back to the levels 
found in healthy animals. At the same time, the expression of 
CD115—necessary for OC differentiation—on both of these 
progenitor populations was decreased following ES-62 treatment. 
Perhaps even more impressively, ES-62-treated CIA animals had 
an altered profile of functional OC maturation ex vivo compared 
to PBS-treated controls, suggesting that even limited exposure 
to ES-62 in  vivo could have a lasting impact on the potential 
for pathogenic osteoclastogenesis in arthritis. With regards to 
how ES-62 modulates the progenitor populations in the BM, it 
is known that this worm product subverts TLR4 and MyD88 
signaling to enact its immunomodulatory effects on cells (36). 
Interestingly, expression of TLR4, and MyD88 is required for 
HSC differentiation to myeloid cells following LPS stimulation 
(37). Thus, MyD88 may serve as a potential target for ES-62 in 
resetting baseline levels of HSCs, and OCPs, with this molecule 
providing the first example of a defined helminth ES product 
rewiring bone-remodeling progenitor populations in  vivo to 
protect against the development of musculoskeletal disease.
In addition to the effects of ES-62 in vivo, the worm product 
directly inhibits OC differentiation in vitro: this ability is remi-
niscent of previous studies showing that a distinct glycoprotein 
within crude ES from the human tapeworm Spirometra erina-
ceieuropaei was able to inhibit in  vitro OC differentiation and 
reduce inflammatory cytokine production although the mole-
cular mechanisms underlying these effects were not investigated 
(38). More recently, Chen et al. (34) and Sarter et al. (39) both 
demonstrated instances where live worm infections were capable 
of reducing inflammatory disease in murine arthritis models, 
thereby resulting in fewer OCs at the inflamed joint (34, 39), with 
the latter group going on to demonstrate that Heligmosomoides 
polygyrus (H)ES was capable of inhibiting the differentiation of 
OCs in  vitro, although again no mechanistic information was 
provided (39). While, similar concentrations of ES-62 and HES 
(50 µg/ml) have been used to inhibit OC differentiation, in vitro 
(39), HES contains the full complement of ES products from H. 
polygyrus [likely hundreds in number (40)] and it is possible that 
only one or two components may exert similar effects to ES-62. 
This suggests that the active ingredient(s) in HES may be more 
potent than ES-62. However, in contrast to HES-induced OC 
inhibition, where the parasite products were present throughout 
the culture, ES-62 and the SMAs exhibited an inhibitory effect on 
cells that had already been exposed to M-CSF and RANKL for 
4 days. Thus, ES-62 and the SMAs were able to prevent the fusion 
and maturation of OCs even at a late stage of differentiation.
The differential effects of ES-62 and the SMAs in vitro with 
respect to differentiation of OCs from BM derived from naïve 
C57BL/6 mice may simply reflect the higher (~10-fold) molar 
concentrations of the SMAs relative to that of the active PC moi-
ety of the parent ES-62 structure. Moreover, the SMAs contain a 
sulfonyl functional group in place of the phosphate group of the 
PC-containing molecules used in this study, which by providing 
additional stability may explain the relative potency of the SMAs 
(especially with respect to PC alone) in inhibiting OC differentia-
tion and functional maturation. Nevertheless, as we have found 
in our previous CIA studies (16, 17), ES-62 appears to exhibit more 
potent effects under inflammatory conditions in vivo relative to its 
direct actions on “normal” isolated cells in vitro and this seems to 
reflect that, rather than suppressing responses per se, ES-62 acts 
to downregulate aberrant patholo gical signals to homeostatically 
restore steady-state responses. Alternatively, in vivo, ES-62 may 
target a cell network or induce systemic cellular or mediator effects 
that we have not yet recapitulated in vitro. Moreover, although 
we have generally found ES-62 to maximally modulate myeloid 
cell responses at 1–2 µg/ml in vitro [e.g., Ref. (18, 19)], we have 
previously shown the worm product to exhibit differential effects 
on naïve and activated B cell responses in vitro when stimulated 
with low or high concentrations (41). Overall, this suggests that 
ES-62 affects particular responses in a concentration and cell-
dependent manner.
Our previous studies revealed that there are some differ-
ences in mechanism of action between the structurally similar 
SMA 11a and 12b despite both being modeled on the PC com-
ponent of ES-62. Thus in CIA, SMA 11a preferentially targets 
IL-17 signaling (17), while SMA 12b predominantly targets 
NRF2 to inhibit, the NLRP3 inflammasome, and IL-1β (19). 
Furthermore, microarray analysis on BM-derived macrophages 
stimulated with SMA 12b highlighted several pathways that 
were affected following SMA treatment and, of importance 
to this study, identified a number of osteoclastogenic targets. 
These included NFATc1 and c-Fos, which are both required for 
the differentiation of OCs (10, 19, 42) and reflecting this, in 
this study, SMA 12b downregulated mRNA levels of the main 
regulator of OC differentiation, NFATc1. The downregula-
tion of NFATc1 mRNA levels likely resulted in the observed 
effects on the expression of mRNA for genes required for OC 
differentiation and function, such as DC-STAMP, cathepsin K, 
and MMP9. Perhaps surprisingly, SMA 11a, unlike SMA 12b, 
was unable to modulate OC-related mRNA transcription in 
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this study. Our previous data on macrophages also indicated 
that exposure to SMA 12b but not 11a for 4 h promoted NRF2 
signaling (19) but our further studies now suggest that 11a also 
induces anti-oxidant responses, albeit this is not seen until 
~24 h (unpublished data). Consistent with this, both SMAs were 
able to generate an anti-oxidant response in the present work as 
shown by increased HMOX-1, GCLC, and GCLM gene expres-
sion by 24 h. NRF2 is a negative regulator of osteoclastogenesis 
as nrf2−/− BM produces higher numbers of OCs compared to 
WT BM as a result of increased ROS production (43), which 
is utilized by OCs to enhance differentiation following both 
M-CSF and RANKL stimulation (11, 12). Both SMA 11a and 
12b increase expression of these NRF-2-regulated anti-oxidant 
genes that inhibit ROS production resulting from M-CSF plus 
RANKL stimulation, suggesting that their ability to generate 
a potent and robust anti-oxidant response prevents the dif-
ferentiation of mature OCs. Although, we have not definitively 
shown that the SMAs utilize NRF2 to drive an anti-oxidant 
response to inhibit OC differentiation, future studies exploiting 
nrf2−/− mouse models might provide valuable insight into the 
role the anti-oxidant response plays in SMA-mediated inhibi-
tion of OC differentiation and functional maturation (32, 43).
Interestingly, inhibition of osteoclastogenesis by ES-62 and the 
SMAs was achieved in BM from naïve animals from both arthri-
tis-prone and more resistant strains of mice. CIA is reproducibly 
induced in DBA/1 mice with approximately 80–100% incidence 
while CIA incidence in C57BL/6 mice can range between 0 and 
60% (28). Thus, in spite of the relative differences in disease sus-
ceptibility between these strains, ES-62 and the SMAs were able 
to inhibit not only the fusion of smaller TRAP+ OCPs into large 
multinucleated OCs, but also the bone resorption activities of 
such OCs in both cases. This may suggest a therapeutic potential 
even in humans highly susceptible to developing disease.
In summary, we show that exposure to the parasitic helminth 
product ES-62 reduces the pool of progenitors in the BM of 
CIA animals and results in an altered course of monocyte/OC 
differentiation. Mechanistically, this is because ES-62, and SMAs 
based on the active PC moiety of ES-62, can inhibit the differ-
entiation and fusion of OCs in vitro and the SMAs are capable 
of inducing NRF2-related anti-oxidant genes in OCs. Together 
these data are representative of a novel area of research linking 
the immunomodulatory capabilities of parasitic helminths and 
osteoimmunology that has perhaps previously been overlooked. 
Therapeutically, this could have ramifications for RA, as well as 
other OC-driven pathologies, as ES-62 not only prevents the 
inflammatory pathology of CIA, but also rewires the effector cells 
to a “safe” phenotype that could provide longer lasting benefits 
beyond current therapeutic interventions.
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